中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

90 records (took 0.054 seconds)

    Substituted acylanilides and methods of use thereof
    2.
    发明授权
    Substituted acylanilides and methods of use thereof 有权
    取代的酰基酰苯胺及其使用方法

    公开(公告)号：US08846756B2

    公开(公告)日：2014-09-30

    申请号：US13868768

    申请日：2013-04-23

    Applicant: James T. Dalton ,  Duane D. Miller

    Inventor： James T. Dalton ,  Duane D. Miller

    IPC: A61K31/275 ,  C07C255/60

    CPC classification number: C07C255/60 ,  C07B2200/07

    Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

    Abstract translation: 本发明提供了SARM化合物及其用于治疗受试者中的多种疾病或病症的用途，所述疾病或病症尤其包括肌肉消瘦疾病和/或病症或骨相关疾病和/或病症。

    ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF
    4.
    发明申请
    ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF 有权
    雌激素受体配体及其使用方法

    公开(公告)号：US20120077845A1

    公开(公告)日：2012-03-29

    申请号：US13215679

    申请日：2011-08-23

    Applicant: James T. DALTON ,  Mitchell S. STEINER ,  Ronald A. MORTON

    Inventor： James T. DALTON ,  Mitchell S. STEINER ,  Ronald A. MORTON

    IPC: A61K31/137 ,  A61P5/26 ,  A61K31/4453 ,  A61K31/167 ,  A61P35/00

    CPC classification number: A61K31/167 ,  A61K31/137 ,  A61K31/4453 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative treatment of prostate cancer, advanced prostate cancer and castration-resistant prostate cancer (CRPC). The compounds of this invention suppress free or total testosterone levels to castrate levels which may be used to treat prostate cancer, advanced prostate cancer, and CRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.

    Abstract translation: 本发明涉及通过减少黄体激素（LH）或独立于男性受试者的LH水平来降低睾酮水平的方法以及治疗，抑制，降低发病率，降低严重性或抑制前列腺癌，晚期前列腺癌的方法 ，抗阉割前列腺癌（CRPC）和姑息治疗前列腺癌，晚期前列腺癌和去势抗原前列腺癌（CRPC）。 本发明的化合物抑制游离或总睾丸激素水平的阉割水平，其可用于治疗前列腺癌，晚期前列腺癌和CRPC，而不引起骨丢失，骨矿物质密度降低，骨折的增加风险，增加的身体脂肪，热 闪烁和/或男子女子气概

    Substituted acylanilides and methods of use thereof
    5.
    发明授权
    Substituted acylanilides and methods of use thereof 有权
    取代的酰基酰苯胺及其使用方法

    公开(公告)号：US08080682B2

    公开(公告)日：2011-12-20

    申请号：US11892595

    申请日：2007-08-24

    Applicant: James T. Dalton ,  Duane D. Miller

    Inventor： James T. Dalton ,  Duane D. Miller

    IPC: C07C255/50 ,  A61K31/275

    CPC classification number: C07C255/60 ,  C07B2200/07

    Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

    Abstract translation: 本发明提供了SARM化合物及其用于治疗受试者中的多种疾病或病症的用途，所述疾病或病症尤其包括肌肉消瘦疾病和/或病症或骨相关疾病和/或病症。

    SARMS and method of use thereof
    7.
    发明授权
    SARMS and method of use thereof 有权
    SARMS及其使用方法

    公开(公告)号：US07772433B2

    公开(公告)日：2010-08-10

    申请号：US11785250

    申请日：2007-04-16

    Applicant: James T. Dalton ,  Duane D. Miller

    Inventor： James T. Dalton ,  Duane D. Miller

    IPC: C07C233/05 ,  A61K31/165

    CPC classification number: C07C255/60 ,  A61K38/09 ,  A61K38/24 ,  A61K38/35 ,  A61K2300/00

    Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, muscle wasting diseases and/or disorders, bone-related diseases and/or disorders, diabetes, cardiovascular disease, renal disease and others.

    Abstract translation: 本发明提供了SARM化合物及其用于治疗受试者中各种疾病或病症的用途，包括肌肉消耗疾病和/或病症，骨相关疾病和/或病症，糖尿病，心血管疾病，肾脏疾病 和别的。

    Multi-substituted selective androgen receptor modulators and methods of use thereof
    8.
    发明授权
    Multi-substituted selective androgen receptor modulators and methods of use thereof 有权
    多取代的选择性雄激素受体调节剂及其使用方法

    公开(公告)号：US07705182B2

    公开(公告)日：2010-04-27

    申请号：US10371155

    申请日：2003-02-24

    Applicant: James T. Dalton ,  Duane D. Miller ,  Mitchell S. Steiner ,  Karen A. Veverka ,  Dong Jin Hwang ,  Jiyun Chen

    Inventor： James T. Dalton ,  Duane D. Miller ,  Mitchell S. Steiner ,  Karen A. Veverka ,  Dong Jin Hwang ,  Jiyun Chen

    IPC: C07C233/05 ,  A61K31/16

    CPC classification number: C07C235/24

    Abstract: This invention provides androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; and/or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

    Abstract translation: 本发明提供雄激素受体靶向剂（ARTA）。 这些药剂定义了一种新的化合物亚类，它们是选择性雄激素受体调节剂（SARM）。 已经发现几种SARM化合物对雄激素受体具有非甾类化合物的意想不到的雄激素和合成代谢活性。 已经发现其他SARM化合物对雄激素受体具有非甾类配体的意想不到的抗雄激素活性。 SARM化合物，单独或作为组合物，可用于a）男性避孕; b）治疗各种激素相关病症，例如与老年雄性雄激素降低有关的病症（ADAM），如疲劳，抑郁，性欲降低，性功能障碍，勃起功能障碍，性腺机能减退，骨质疏松症，脱发，贫血， 肥胖，肌营养不良，骨质减少，骨质疏松症，良性前列腺增生，情绪和认知和前列腺癌的改变; c）治疗与男性雄激素降低相关的病症（ADIF），如性功能障碍，性欲降低，性腺机能减退，肌营养不良，骨质减少，骨质疏松症，认知和情绪改变，抑郁症，贫血，脱发，肥胖，子宫内膜异位症，乳腺癌 癌症，子宫癌和卵巢癌; d）治疗和/或预防急性和/或慢性肌肉消瘦病症; e）预防和/或治疗干眼症状; f）口服雄激素替代疗法; 和/或g）降低前列腺癌的发生率，停止或导致消退。

Patent Agency Ranking